Dear Editor,

Since early December 2019, a large outbreak of pneumonia caused by a novel coronavirus (COVID-19) had emerged in Wuhan, China (Wu *et al.*[@CR12], [@CR13]; Zhou *et al.*[@CR15]; Zhu *et al.*[@CR16]; Jiang and Shi [@CR5]). Similar to severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), the new coronavirus also belongs to *Betacoronavirus*, and shares highest sequence identity to three SARS-like CoVs of bat origin (bat_CoV_RaTG13: 96.0%, bat-SL-CoVZC45: 88.0% and bat-SL-CoVZXC21: 87.2%) (Zhou *et al.*[@CR15]). Although only sharing about 79.5% genomic sequence identity to SARS-CoV, the new virus was demonstrate to use the same receptor angiotensin converting enzyme II (ACE2) for human infection as SARS-CoV (Lu *et al.*[@CR8]; Wu [@CR11]; Zhou *et al.*[@CR15]) and is officially named as SARS-CoV-2 (also known as 2019-nCoV) (Gorbalenya *et al.*[@CR3]). Epidemically data showed that the virus has strong human-to-human transmission ability, and it is spread by droplets produced by coughing and sneezing, infecting susceptible subjects through direct contacts and other possible transmission routes (*e.g*. fecal-mouth transmission) (Guan *et al.*[@CR4]; Li *et al.*[@CR7]).

As of Mar. 27, 2020, the outbreak had resulted in 533,464 laboratory-confirmed cases, including 24,097 deaths around the world. Currently, there lacks suitable antiviral drugs or vaccines for SARS-CoV-2. Early, rapid, and reliable diagnostic assays for SARS-CoV-2 is of top priority to facilitate public health interventions that can reduce or avoid further spread of SARS-CoV-2 (Dennis Lo and Chiu [@CR2]). Quantitative Real-time PCR (qPCR) is a robust technology for reliable laboratory diagnosis, and routinely used to detect causative pathogens. Since the release of genomic sequence of SARS-CoV-2 in Jan. 11, 2020, many TaqMan probe-based RT-qPCR assays had been developed and used in confirmation of large number of SARS-CoV-2 infections during the outbreak (Chu *et al.*[@CR1]; Dennis Lo and Chiu [@CR2]). Facing the on-going increase of suspected cases and potential contacts, however, the detection capacity of RT-qPCR assays have shown limitations in speed and volume because these assays require sophisticated equipment and highly trained personnel, and are relatively time-consuming (about 1.5--2 h). Therefore, there is an urgent demand for faster and sensitive Point-of-Care testing (POCT) assays to facilitate rapid detection of SARS-CoV-2 infection. However, there is no POCT assay available for SARS-CoV-2 yet. Here, we present a novel visual reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for rapid and sensitive detection of SARS-CoV-2 using mismatch-tolerant technique.

Based on SARS-CoV-2 genomic sequences, we designed six sets of LAMP primers (4, 1, and 1 in *N*, *S* and *RdRp* genes, respectively) using the open access Primer Explorer V.5 software tool (<http://primerexplorer.jp/>). We firstly excluded primer sets with non-specific amplification, and then selected the primers having high amplification efficiency using the conventional RT-LAMP method. The *RdRp* primers showed higher amplification efficiency, and were selected to establish the SARS-CoV-2 detection assay using the mismatch-tolerant RT-LAMP method (Li *et al.*[@CR6]; Zhou *et al.*[@CR14]). The *RdRp* primer information is shown in Fig. [1](#Fig1){ref-type="fig"}A, [1](#Fig1){ref-type="fig"}B. A 25 µL reaction system includes 1 × isothermal amplification buffer, 6 mmol/L MgSO~4~, 1.4 mmol/L dNTPs, 8 units of WarmStart Bst 3.0 DNA polymerase, 7.5 units of WarmStartR RT, 0.15 unit of Q5 High-Fidelity DNA Polymerase, 1.6 μmol/L each of primers of FIP and BIP, 0.2 μmol/L each of primers of F3 and B3, 0.8 μmol/L of loop primer FLP and BLP, and 0.4 mmol/L SYTO 9 (Life technologies, Carlsbad, CA, United States). Three types of polymerases were purchased from New England Biolabs (Beverly, MA, United States). Three microliters of RNA were used for the RT-LAMP assays. The RT-LAMP reaction was performed at 63 °C for 50 min for real-time monitoring using the Light Cycler 96 real-time PCR System (Roche Diagnostics, Mannheim, Germany).Fig. 1**A** Location of the primers in SARS-CoV-2 genome. **B** Sequence comparison among seven human coronaviruses (SARS-CoV2, SARS-CoV, MERS-CoV, OC43, HKU1, NL63 and 229E). **C** Cross-reactivity test of the novel SARS-CoV-2 RT-LAMP assay to other common respiratory viruses. Tested common respiratory viruses include HCoV-HKU-1, HCoV-NL63, HCoV-OC43, HCoV-229E, influenza A, B, and C viruses, parainfluenza viruses type 1--3, enterovirus, respiratory syncytial virus A and B groups, human rhinovirus, human metapneumovirus, adenovirus and bocavirus. RNA from a COVID-19 patient was used as positive control (PC). NTC, non-template control. **D** Sensitivity test of the novel SARS-CoV-2 RT-LAMP assay. Positive amplification was defined only when all three replicates are successfully amplified. NTC: non-template control. **E** Visual detection of SARS-CoV-2 by the colorimetric RT-LAMP assay. **E**-**a** RNA standards; **E**-**b** Clinical samples. NTC: non-template control.

To determine the specificity of the SARS-CoV-2 RT-LAMP assay, 15 clinical samples positive for common respiratory viruses (including influenza A, B, and C viruses, parainfluenza viruses type 1--3, enterovirus, respiratory syncytial virus (RSV) A and B groups, HCoV-HKU-1, HCoV-NL63, human rhinovirus, human metapneumovirus, adenovirus and bocavirus), and two human coronavirus standard strains HCoV-OC43 (VR-1558) and HCoV-229E (VR-740) were tested. None or very weak amplification signals were observed for all 17 respiratory viruses after 50 min, indicating good specificity of the assay (Fig. [1](#Fig1){ref-type="fig"}C). Although we did not test the specificity for SARS-CoV and MERS-CoV because of the lack of clinical samples or standard strains, the sequence comparison suggests the RT-LAMP can also amplify SARS-CoV due to high sequence similarity (Fig. [1](#Fig1){ref-type="fig"}B).

To prepare RNA standard, a SARS-CoV-2 *RdRp* fragment (15,034--15,274 nt in Wuhan-Hu-1, GenBank: MN908947.3) was amplified from positive clinical sample with T7-promoter-containing primers, and then the products were subjected to in vitro transcription. RNA products were quantitated by Nanodrop 2000C (Thermo, USA). A tenfold serial dilution of RNA standard from 10^6^ to 1 copies per μL was used to test the sensitivity of the SARS-CoV-2 RT-LAMP assay. The result showed that the RT-LAMP can detect as few as 3 copies of SARS-CoV-2 RNA per 25 μL reaction (Fig. [1](#Fig1){ref-type="fig"}D). In particular, amplification curves of template inputs \> 300 copies appeared within 20 min, showing a fast amplification (Fig. [1](#Fig1){ref-type="fig"}D).

For the POCT diagnosis of SARS-CoV-2 infection in the resource-poor settings, we developed the assay into a visual detection using WarmStart Colorimetric LAMP 2 × Master Mix (New England Biolabs, Beverly, MA, United States). A 25 µL reaction system includes 1 × WarmStart Colorimetric LAMP buffer, 0.15 unit of Q5 High-Fidelity DNA Polymerase, 1.6 μmol/L each of primers of FIP and BIP, 0.2 μmol/L each of primers of F3 and B3, and 0.8 μmol/L of loop primer FLP and BLP. The reactions were performed at 63 °C, and the color change was observed at the 30-, 40-, and 50-min time points. The visual detection system contains a pH-sensitive indicator dye cresol red. Because LAMP amplification results in a significant pH change of buffer from an initial alkaline condition to a final acidic condition (Tanner *et al.*[@CR10]), the color change of cresol red from burgundy to orange or yellow indicates a positive reaction. The assay gave a clear color indication for all tested samples during 30--50 min (data not shown). We selected 40 min as the cut-off for the visual assay (Fig. [1](#Fig1){ref-type="fig"}E). The sensitivity of the colorimetric RT-LAMP assay for SARS-CoV-2 was 30 copies per reaction, slightly lower than the real-time monitoring (Fig. [1](#Fig1){ref-type="fig"}E).

To evaluate the performance of the colorimetric RT-LAMP assay for SARS-CoV-2, we compared it with the SARS-CoV-2 RT-qPCR kit (Liferiver Bio, Shanghai, China) using 24 clinical samples. All 17 positive samples as shown by the RT-qPCR assay (CT values: 28.8--40) were also positive by the novel RT-LAMP assay, demonstrating a 100% consistency (Supplementary Table S1).

The severity of SARS-CoV-2 pandemic had exceeded SARS-CoV. In Jan. 30, 2020, The COVID-19 pandemic was declared as a public health emergency of international concern by WHO. Early diagnosis and timely implementation of intervention and quarantine measures are very crucial for prevention and control of emerging infectious diseases such as COVID-19 (Dennis Lo and Chiu [@CR2]). The rapid identification of SARS-CoV-2 and subsequent release of its genome sequence are very important in a public health perspective, and these made the development of SARS-CoV-2 diagnostic assays possible. Many RT-qPCR assays have been developed and used in the confirmation of SARS-CoV-2 infection during the pandemic (Chu *et al.*[@CR1]). However, high level facility requirement of RT-qPCR assays is a major factor limiting the confirmation speed and causing a large number of suspected cases waiting for tests as these assays are not available in primary care and community hospitals or health care centers where there were no real-time thermal cycler and trained professional. On the other hand, the median incubation period of COVID-19 is 4 days (range 0--24.0 days), and the longest incubation period observed is 24 days (Guan *et al.*[@CR4]). In particular, some infected individuals did not develop obvious clinical symptoms (Rothe *et al.*[@CR9]). The long incubation period and asymptomatic infections imply a huge risk of virus transmission to other people (Wu *et al.*[@CR12], [@CR13]). In this respect, POCT detection tools that can be performed in fields and even patients' own houses have a huge advantage, and should be developed.

LAMP is the most commonly used isothermal amplification technique for POCT diagnosis due to its high sensitivity, rapid reaction, simple operation, and easy observation of results. Recently, we developed a mismatch-tolerant LAMP method by adding 0.15 U of high-fidelity DNA polymerase (Zhou *et al.*[@CR14]). The main difference between the mismatch-tolerant LAMP and the conventional ones is the inclusion of an additional amount of high-fidelity DNA polymerase in the former, which largely improves the sensitivity and reaction speed (Li *et al.*[@CR6]; Zhou *et al.*[@CR14]). Using this mismatch-tolerant technique, we developed a one-step single-tube RT-LAMP assay for detection of SARS-CoV-2. The assay can be performed at 63 °C for 40 min in a real-time or a regular thermal cycler, or any heating block such as a dry incubator or a water bath. The result is easily judged by the color change from burgundy to orange or yellow. Compared to the conventional LAMP protocol, the novel SARS-CoV-2 RT-LAMP assay is more rapid and more sensitive. The sensitivity of the assay is 30 copies per reaction. Although we did not test the specificity for SARS-CoV and MERS-CoV due to a lack of clinical samples, we sound the assay exhibited specificity by testing 17 common human respiratory viruses, including four other human coronaviruses OC43, 229E, HKU-1 and NL63. The evaluation with 24 clinical samples showed that all 17 COVID-19 patients in Nantong city were positive for SARS-CoV-2 by both the RT-LAMP and the RT-qPCR assays, showing a full consistence.

In conclusion, the novel visual RT-LAMP assay is a simple, rapid, and sensitive approach for detection of SARS-CoV-2, and it is ready for application in primary care and community hospitals or health care centers, and even patients' own houses in response to the current SARS-CoV-2 epidemic because the assay does not require sophisticated equipment and skilled personnel. Furthermore, it is also ready to be used in fields for screening samples from wild animals and environments to facilitate the identification of potential intermediate hosts that mediate the cross-species transmission of SARS-CoV-2 from bats to humans.
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